Insiders who reported open-market trades in the last 12 months at the companies MPM BioVentures 2014, L.P. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Kush Parmar - $3.65M in TRDA purchases and sales in the last 12 months
MPM BioVentures 2014, L.P. is an investment firm, tracked as 10% Owner of Entrada Therapeutics, Inc. (TRDA). InsiderAlpha holds 15 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has MPM BioVentures 2014, L.P. submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has MPM BioVentures 2014, L.P. been buying or selling stock?
Recorded transactions: 0 open-market purchases and 43 open-market sales ($11.82M) across all tracked filings.
MPM BioVentures 2014, L.P. is 10% Owner of Entrada Therapeutics, Inc. (TRDA). 15 SEC Form 4 filings on record going back to 2024, most recently on 9 September 2026. Most recent open-market trade: sold $206K of TRDA on 9 September 2026. Lifetime open-market sales: $11.82M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by MPM BioVentures 2014, L.P..
InsiderAlpha's records for MPM BioVentures 2014, L.P. go back to 2024: 15 primary Form 4 filings, an average of 5.0 per year. 28 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
